Business
RepliCel Life Sciences Inc. Announces Brokered Private Placement
RepliCel Life Sciences Inc. Announces Brokered Private Placement.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n\n\n\nRepliCel Life Sciences Inc. Announces Brokered Private Placement\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nRepliCel Life Sciences Inc. Announces Brokered Private Placement\nCanada NewsWire\nVANCOUVER, Oct. 20, 2015\n\n\n\n/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/\n\n\n\nVANCOUVER, Oct. 20, 2015 /CNW/ - RepliCel Life Sciences Inc. (\"RepliCel\" or the \"Company\") (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to announce it intends to undertake a brokered private placement of units (\"Units\"), on a commercially reasonable basis, for gross proceeds of up to $2,000,000. Each Unit will be priced at $0.31 and will consist of one common share of the Company (each, a \"Share\") and one share purchase warrant (each a \"Warrant\"), with each Warrant entitling the holder to purchase one additional Share at a price of $0.40 per Share for a period of 24 months from the closing of the private placement. Euro Pacific Canada Inc. and Richardson GMP Limited (collectively, the \"Agents\") are acting as the lead agents in connection with this brokered financing. \n\nAll securities issued pursuant to the financing will be subject to a statutory hold period expiring four months and one day after closing of the financing. Completion of the financing is subject to a number of conditions, including, without limitation, entry into an agency agreement with the Agents for the brokered financing and receipt of all regulatory approvals, including approval of the TSX Venture Exchange.\n\nProceeds of the financing are anticipated to be used for clinical trials, research and development and general working capital.\n\nNone of the securities issued in connection with the financing will be registered under the United States Securities Act of 1933, as amended (the \"1933 Act\"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registratio...